Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2010The Pediatric Infectious Disease Journal

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMatthew D. SnapeUniversity of WarwickCKChaam L. KlingerUniversity of OxfordEDElvis D. DanielsPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Snape et al. (2010) studied this question.

synapsesocial.com/papers/6a6a9fcf47a1bfb288f2d8fahttps://doi.org/10.1097/inf.0b013e3181faa6be
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C2008 · 157 citations
  2. 2The Protective Level of Serum Antibodies to the Capsular Polysaccharide of Haemophilus influenzae Type b1983 · 545 citations
  3. 3Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers2010 · 145 citations
  4. 4Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S1995 · 268 citations